Navigating The Complex Realities Of Biomarker Testing In Oncology

The move towards precision medicine within oncology has had drastic effects on the number of relevant biomarkers and their tests. According to IQVIA’s Oncology Dynamics database, on average, a cancer patient today gets tested for at least 1 predictive biomarker, with greater evolution of testing in certain indications, often with high incidence and high unmet need. Looking ahead, we see that the importance of biomarkers will increase, as more targeted products are launched, adding to the complexity observed in the oncology treatment environment today. 

The focus of this white paper is to highlight the rapidly evolving biomarker landscape in oncology from clinical development to regulatory uncertainties to commercial implications. It will focus on the key challenges and success factors involved in launching targeted therapies with biomarkers and/or in vitro diagnostics, outline how to navigate the complex realities of biomarkers and how the industry needs to adapt for targeted therapies to ultimately reach patients without creating too much of a burden on the healthcare system.